A Phase III Double-blind, Randomised Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria

Trial Profile

A Phase III Double-blind, Randomised Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria

Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2018

At a glance

  • Drugs Lyophilised Oxalobacter formigenes (Primary)
  • Indications Hyperoxaluria
  • Focus Registrational; Therapeutic Use
  • Acronyms ePHex
  • Sponsors OxThera
  • Most Recent Events

    • 10 Jul 2018 According to an OxThera media release, All clinics participating in the study are approved by Competent authorities in Europe and US and are initiating patient screening. The last patient is expected to complete study procedures in 2019.
    • 14 Mar 2018 According an OxThera media release, the first patient has been randomized in this trial.
    • 09 Feb 2018 Planned End Date changed from 1 Sep 2019 to 1 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top